XELOX与FOLFOX化疗方案治疗晚期结直肠癌患者的效果比较

Comparison of effects of XELOX and FOLFOX chemotherapy regimens in treatment of patients with advanced colorectal cancer

目的:比较XELOX与FOLFOX化疗方案治疗晚期结直肠癌患者的效果。方法:回顾性分析2018年5月至2020年6月该院收治的80例晚期结直肠癌患者的临床资料,按照治疗方案不同将其分为研究组41例与对照组39例。对照组予以FOLFOX化疗方案(氟尿嘧啶+亚叶酸钙+奥沙利铂)治疗,研究组予以XELOX方案化疗(奥沙利铂+卡培他滨)治疗,比较两组疾病控制率、治疗前后血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)]水平、T细胞亚群指标(CD4^(+)、CD3^(+)、CD8+)水平和不良反应发生率。结果:两组疾病控制率比较,差异无统计学意义(P>0.05);治疗后,两组血清CEA、CA125、CA19-9水平均低于治疗前,差异有统计学意义(P<0.05),但组间比较,差异无统计学意义(P>0.05);治疗后,研究组CD4^(+)、CD3^(+)、CD8+水平均高于对照组,差异有统计学意义(P<0.05);研究组骨髓抑制、腹泻、恶心呕吐等不良反应发生率均低于对照组,差异有统计学意义(P<0.05)。结论:XELOX与FOLFOX化疗方案治疗晚期结直肠癌患者的疾病控制率和对血清肿瘤标志物水平的影响相当,但XELOX化疗方案T细胞亚群指标水平和不良反应发生率均低于FOLFOX化疗方案。

Objective:To compare effects of XELOX and FOLFOX chemotherapy regimens in treatment of patients with advanced colorectal cancer.Methods:The clinical data of 80 patients with advanced colorectal cancer admitted to our hospital from May 2018 to June 2020 were retrospectively analyzed.According to different treatment regimens,they were divided into study group(41 cases)and control group(39 cases).The control group was treated with FOLFOX chemotherapy(Fluorouracil+Calcium leucovorin+Oxaliplatin),while the study group was treated with XELOX chemotherapy(Oxaliplatin+Capecitabine).The disease control rate,THE serum tumor marker levels[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),and carbohydrate antigen 19-9(CA19-9)],the T cell subset indicator levels(CD4^(+),CD3^(+),CD8^(+))and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:There was no significant difference in the disease control rate between the two groups(P>0.05).After the treatment,the levels of serum CEA,CA125 and CA19-9 in the two groups were lower than those before the treatment,and the differences were statistically significant(P<0.05);however,there were no significant differences between the two groups(P>0.05).After the treatment,the levels of CD4^(+),CD3^(+),and CD8^(+)in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).Further,the incidence rates of adverse reactions such as bone marrow suppression,diarrhea,nausea and vomiting in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusions:The disease control rates and the effects on the serum tumor marker levels of XELOX and FOLFOX chemotherapy regimens are comparable in the treatment of the advanced colorectal cancer patients,but the levels of T-cell subsets and the incidence of adverse reactions of XELOX chemotherapy regimen are lower than FOLFOX chemotherapy regimen.